Medicare AdvantageAdministrativeMedium impact
MA08.083l, Leuprolide (Camcevi™, Eligard®, Fensolvi®, Lupron Depot®)
Independence Blue Cross·Oncology, Urology, Endocrinology·Pharmacy
Effective date
Dec 29, 2025
We identified it
Jun 19, 2026
Summary
Policy MA08.083l for Leuprolide (Camcevi, Eligard, Fensolvi, Lupron Depot) has been updated effective 12/29/2025 with changes to medical necessity criteria and general guidelines. The billing team must review the full policy text to identify specific coverage requirements, prior authorization mandates, and any billing code or documentation changes that may affect claims processing for leuprolide injections.
Action Required
By 12/29/2025: Billing team and providers must obtain and review the complete policy text at https://medpolicy.ibx.com/ibc/ma/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=12&FilterField2=MPSiteActivityLogYear&FilterValue2=2025#medicare-advantage-ma08-083l-leuprolide-camcevi-eligard-fens. Identify all leuprolide claims currently in-flight and cross-reference against updated medical necessity criteria. Update billing software with any new prior authorization requirements, coverage limitations, or documentation standards. Alert providers prescribing leuprolide to changes in medical necessity documentation. Train front-desk and prior-auth staff on new requirements. Failure to comply may result in claim denials for leuprolide injections under Medicare Advantage plans.